Effectiveness of Sinopharm’s BBIBP-CorV Booster Vaccination Against COVID-19-Related Severe and Critical Cases and death in Morocco During the Omicron Wave DOI Creative Commons
Jihane Belayachi,

Abdelkader Mhayi,

Hind Majidi

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Sept. 25, 2023

Objective This study investigates the effectiveness of booster doses on Omicron wave in Morocco against COVID-19 severe and critical hospitalizations deaths; Participants/methods uses nationally representative data from 15 December 2021 to 31 January 2022. To investigate inactivated vaccine BBIBP-CorV (Vero Cells) Sinopharm morocco by using real-world established statistics cases, deaths vaccinations. Statistical Analyses The screening method was used estimate or hospitalization COVID-19-related deaths. were grouped by, age subgroup, sex, week, geographical area analyzed binary logistic regression with an offset for coverage. Results overall sinopharm VE is 89% (95% CI 85 92) effective curbing death, 81% 78 84 hospitalization. Death-related 86% 81 90) patients aged 1Z65 years, 96% 90 98) those < 65 95% 88 no risk factor patient was, 91% 94) 1 factor; 90% 83 95) 2 factors; 72% 52 84) 3 factors more. Severe VE, 78% 74 82) 87% 82 80 80% 73 70 85) 68 86) Conclusions Boosters are increasing protection variant-related death reduced older higher factors. These findings emphasize importance targeted vaccination strategies different demographic groups underscore protective benefits third vaccine.

Language: Английский

Epidemiology of Respiratory Infections during the COVID-19 Pandemic DOI Creative Commons
Nicola Principi, Giovanni Autore,

Greta Ramundo

et al.

Viruses, Journal Year: 2023, Volume and Issue: 15(5), P. 1160 - 1160

Published: May 13, 2023

To face the COVID-19 outbreak, a wide range of non-pharmaceutical interventions (NPIs) aimed at limiting spread virus in communities, such as mask-wearing, hand hygiene, social distancing, travel restrictions, and school closures, were introduced most countries. Thereafter, significant reduction new asymptomatic symptomatic cases occurred, although there differences between countries according to type duration NPIs. In addition, pandemic has been accompanied by variations global incidence diseases due common non-SARS-CoV-2 respiratory viruses some bacteria. this narrative review, epidemiology infections during is detailed. Moreover, factors that could have had role modifying traditional circulation pathogens are discussed. A literature analysis shows NPIs important cause general influenza syncytial infection first year pandemic, different sensitivity each NPIs, measures used, well interference among may played modulating viral circulation. Reasons for increase incidences Streptococcus pneumoniae group seem strictly linked immunity debt reducing bacterial superimposed infections. These results highlight importance pandemics, need monitor infectious agents similar those caused agents, make efforts improve coverage with available vaccines.

Language: Английский

Citations

83
Effectiveness of Sinopharm’s BBIBP-CorV Booster Vaccination against COVID-19-Related Severe and Critical Cases and Deaths in Morocco during the Omicron Wave DOI Creative Commons
Jihane Belayachi,

Abdelkader Mhayi,

Hind Majidi

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(3), P. 244 - 244

Published: Feb. 27, 2024

Objective: This study investigates the effectiveness of 1st booster dose against COVID-19 severe and critical hospitalizations deaths occurring due to Omicron wave in Morocco. Participants/methods: uses nationally representative data on from 15 December 2021 31 January 2022. The aim is investigate inactivated vaccine BBIBP-CorV (Sinopharm) Morocco using real-world established statistics cases, vaccinations. Statistical Analyses: screening method was used estimate or hospitalization COVID-19-related deaths. were grouped by, age subgroup, sex, week, geographical area analyzed binary logistic regression with an offset for coverage. Results: overall VE 89% (95% CI 85 92) effective curbing deaths, 81% 78 84 severe/critical hospitalizations. Death-related 86% 81 90) patients aged ≥65 years, 96% 90 98) those <65 95% 88 no-risk factor patients, 91% 94) 1 risk factor, 90% 83 95) 2 factors, 72% 52 84) 3 factors more. Severe/critical 78% 74 82) 87% 82 80 80% 73 70 85) 68 86) Conclusions: boosters are increasing protection variant-related reduced older higher factors. These findings emphasize importance targeted vaccination strategies different demographic groups underscore protective benefits first vaccine.

Language: Английский

Citations

1
Vaccine effectiveness in reducing COVID-19-related hospitalization after a risk-age-based mass vaccination program in a Chilean municipality: A comparison of observational study designs DOI Creative Commons
Cinthya Urquidi, Alejandro Sepúlveda-Peñaloza, María Teresa Valenzuela

et al.

Vaccine, Journal Year: 2024, Volume and Issue: 42(18), P. 3851 - 3856

Published: May 15, 2024

Case-control studies involving test-negative (TN) and syndrome-negative (SN) controls are reliable for evaluating influenza rotavirus vaccine effectiveness (VE) during a random vaccination process. However, there is no empirical evidence regarding the impact in real-world mass campaigns against SARS-CoV-2 using TN SN controls.

Language: Английский

Citations

1
Effectiveness of Sinopharm’s BBIBP-CorV Booster Vaccination Against COVID-19-Related Severe and Critical Cases and death in Morocco During the Omicron Wave DOI Creative Commons
Jihane Belayachi,

Abdelkader Mhayi,

Hind Majidi

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Sept. 25, 2023

Objective This study investigates the effectiveness of booster doses on Omicron wave in Morocco against COVID-19 severe and critical hospitalizations deaths; Participants/methods uses nationally representative data from 15 December 2021 to 31 January 2022. To investigate inactivated vaccine BBIBP-CorV (Vero Cells) Sinopharm morocco by using real-world established statistics cases, deaths vaccinations. Statistical Analyses The screening method was used estimate or hospitalization COVID-19-related deaths. were grouped by, age subgroup, sex, week, geographical area analyzed binary logistic regression with an offset for coverage. Results overall sinopharm VE is 89% (95% CI 85 92) effective curbing death, 81% 78 84 hospitalization. Death-related 86% 81 90) patients aged 1Z65 years, 96% 90 98) those < 65 95% 88 no risk factor patient was, 91% 94) 1 factor; 90% 83 95) 2 factors; 72% 52 84) 3 factors more. Severe VE, 78% 74 82) 87% 82 80 80% 73 70 85) 68 86) Conclusions Boosters are increasing protection variant-related death reduced older higher factors. These findings emphasize importance targeted vaccination strategies different demographic groups underscore protective benefits third vaccine.

Language: Английский

Citations

0